Since approval of tocilizumab (TCZ) for treatment of rheumatoid arthritis (RA) and juvenile idiopathic arthritis (JIA), interleukin 6 (IL-6) pathway inhibition was evaluated in trials of TCZ and other agents targeting the IL-6 receptor and ligand in various RA populations and other inflammatory diseases. This consensus document informs on interference with the IL-6 pathway based on evidence and expert opinion.
Smolen, J., Schoels, M., Nishimoto, N., Breedveld, F., Burmester, G., Dougados, M., Emery, P., Ferraccioli, G., Gabay, C., Gibofsky, A., Gomez Reino, J., Jones, G., Kvien, T., Murakami, M., Betteridge, N., Bingham, C., Bykerk, V., Choy, E., Combe, B., Cutolo, M., Graninger, W., Lanas, A., Martin Mola, E., Montecucco, C., Ostergaard, M., Pavelka, K., Rubbert Roth, A., Sattar, N., Scholte Voshaar, M., Tanaka, Y., Trauner, M., Valentini, G., Winthrop, K., De Wit, M., Van Der Heijde, D., Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions, <<EARD>>, 2013; 72 (4): 482-492. [doi:10.1136/annrheumdis-2012-202469] [http://hdl.handle.net/10807/41188]
Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions
Ferraccioli, Gianfranco;
2013
Abstract
Since approval of tocilizumab (TCZ) for treatment of rheumatoid arthritis (RA) and juvenile idiopathic arthritis (JIA), interleukin 6 (IL-6) pathway inhibition was evaluated in trials of TCZ and other agents targeting the IL-6 receptor and ligand in various RA populations and other inflammatory diseases. This consensus document informs on interference with the IL-6 pathway based on evidence and expert opinion.
| File | Dimensione | Formato | |
|---|---|---|---|
|
482.full.pdf
accesso aperto
Tipologia file ?:
Versione Editoriale (PDF)
Licenza:
Creative commons
Dimensione
249.02 kB
Formato
Adobe PDF
|
249.02 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
